Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, announced today that it has raised $25 million in a Series A investment from Vida Ventures and Westlake Village BioPartners, both of which were founding investors, as well as Gilead Sciences (NASDAQ: GILD). Proceeds from the financing will be used to … [Read more...] about Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences